Physician profile
Van Thy Nguyen
NPI 1861003592
$963.60
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $227 · 2023: $130 · 2024: $169 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.44 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $167.82 | 2021-2023 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $102.02 | 2022 | |
| Pfizer INC. | $72.56 | 2023-2024 | |
| Lilly USA, LLC | $62.54 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $44.16 | 2021-2023 | Rexulti |
| International Rehabilitative Sciences, INC | $37.95 | 2025 | Rs-4i Plus With Intersperse |
| Mayne Pharma Commercial LLC | $27.78 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.68 | 2021 | |
| Medtronic, INC. | $25.04 | 2024 | Intellis Adaptivestim |
| Abbvie INC. | $24.37 | 2022 | |
| Astellas Pharma US INC | $22.73 | 2025 | Veozah |
| Dexcom, INC. | $22.60 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $20.02 | 2024 | Inspire |
| Biomarin Pharmaceutical INC. | $18.21 | 2024 | Voxzogo 1.2mg |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.86 | 2022 | |
| Radius Health, INC. | $16.99 | 2023 | Tymlos |
| Amgen INC. | $13.84 | 2022 | |
| Currax Pharmaceuticals LLC | $13.41 | 2021 | |
| Genentech USA, INC. | $3.36 | 2021 | |
| Medline Industries LP | $3.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.